Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 4/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21897625 | 0.85 | GABRG2 (0.31) | GABRG2GABRB3GABRA5 | |
| SCHEMBL21008282 | 0.73 | IRAK4 (0.32) | — | |
| SCHEMBL21432426 | 0.71 | GABRG2 (0.33) | GABRG2GABRB3GABRA5 | |
| SCHEMBL22854641 | 0.67 | HSD17B10 (0.47) | GABRG2GABRB3GABRA5 | |
| SCHEMBL25768442 | 0.65 | HSD17B10 (0.50) | — | |
| SCHEMBL19708457 | 0.63 | — | — | |
| SCHEMBL22854433 | 0.63 | GABRG2 (0.31) | GABRG2GABRB3GABRA5 | |
| SCHEMBL22867622 | 0.60 | DRD3 (0.34) | — | |
| SCHEMBL22103054 | 0.60 | HTR2C (0.30) | — | |
| SCHEMBL16248348 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200147235-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | GABRG2 1526/4885GABRB3 1193/4885GABRA5 850/4885 |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | GABRG2 416/4885GABRB3 621/4885GABRA5 645/4885 |
| US-20200147235-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | GABRG2 416/4885GABRB3 621/4885GABRA5 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.